Synedica peptides: TGA says stop using them

Australia’s Therapeutic Goods Administration (TGA) advises consumers to stop using Synedica-branded peptide products. Its 5 November 2026 safety advisory reported that tested products did not contain what their labels claimed.

The TGA could not detect TB-500 in tested Synedica BPC 157 & TB 500 10 mg, KLOW 80 mg, and BARBIE KLOW 100 mg products, despite their labels listing it. Tested Synedica Retatrutide 10 mg products contained less retatrutide than the label stated, with significant variation between samples. These are findings about the tested samples, not a claim that every peptide product has the same composition.

If you have a Synedica-branded peptide product, stop using it and take any remaining product to your local pharmacy for safe disposal. If you have used one and have concerns about your health, speak with a health professional. Suspected side effects can also be reported to the TGA.

Synedica-branded peptide products have not been assessed by the TGA for quality, safety or efficacy, and their place of manufacture has not been approved by the TGA. The regulator warns that labels on these products cannot reliably tell consumers what substance or amount they are receiving.

Health products promoted online can look convincing without meeting Australian regulatory standards. Before buying medicines online, seek advice from a pharmacist or other health professional and check the TGA’s information. General public-health information, not individual medical advice.